Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 139-144 , March 2010

Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention

  • Michael Staehler, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-89-7095-3722; fax: +49-89-7095-6722
    • ,
  • Nico Haseke, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Ekaterina Zilinberg, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Thomas Stadler, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Alexander Karl, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Michael Siebels, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Hans-Roland Dürr, M.D.

      Affiliations

    • Department of Orthopedics, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Sabine Siegert, M.D.

      Affiliations

    • Department of Pathology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Karl W. Jauch, M.D.

      Affiliations

    • Department of Surgery, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Christiane J. Bruns, M.D.

      Affiliations

    • Department of Surgery, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Christian G. Stief, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany

Received 17 March 2008 ,Revised 31 March 2009 ,Accepted 31 March 2009.

References 

  1. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site [database on the Internet] 2008.
  2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  4. Staehler M, Stenzl A, Dietrich PY, et al. A phase I study to evaluate safety, immunogenicity and anti-tumor activity of the multi-peptide vaccine IMA901 in renal cell carcinoma patients (RCC). Proceedings of the 2007 ASCO Annual Meeting, June, Chicago, IL J Clin Oncol. 2007;25(Suppl June 20):18S;5098
  5. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–141
  6. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004;22:1188–1194
  7. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4:455–468
  8. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. Proceedings of the 2007 ASCO Annual Meeting, Part I J Clin Oncol. 2007;25(Suppl June 20):18S;5011
  9. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. Proceedings of the 2007 ASCO Annual Meeting, Part I J Clin Oncol. 2007;25(Suppl June 20):18S;5010
  10. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proceedings of the 2007 ASCO Annual Meeting, Part I J Clin Oncol. 2007;25(Suppl June 20):18S;5026
  11. Heng DY, Rini BI, Garcia J, et al. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2007;5:446–451
  12. Rini BI, Shaw V, Rosenberg JE, et al. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer. 2006;5:232–234
  13. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463
  14. Durr HR, Maier M, Pfahler M, et al. Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop. 1999;367:283–290
  15. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002;73:1082–1087
  16. Thelen A, Jonas S, Benckert C, et al. Liver resection for metastases from renal cell carcinoma. World J Surg. 2007;31:802–807

PII: S1078-1439(09)00105-7

doi: 10.1016/j.urolonc.2009.03.033

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 139-144 , March 2010

Article Tools

* Image Usage & Resolution